吉西他滨诱导的转移性胰腺腺癌患者外周血管疾病及持久反应：一例报告
Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report.
作者信息
Fabien Moinard-Butot, Elodie Poprawa, Anna Schohn, Addeo Pietro, Meher Benabdelghani
机构信息
Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France.
Department of Supportive Care, Institut de cancérologie Strasbourg Europe, Strasbourg 67200, France.
出版信息
World J Clin Cases. 2023 Feb 26;11(6):1372-1378. doi: 10.12998/wjcc.v11.i6.1372.
BACKGROUND
Gemcitabine is an antimetabolite used in the treatment of pancreatic cancer. One of the side effects of gemcitabine is vascular toxicity. Here, we report the case of a patient treated with gemcitabine who had peripheral vascular disease concomitant with a prolonged antitumor response.
CASE SUMMARY
A 75-year-old man was diagnosed with locally recurrent pancreatic cancer. Partial response was achieved after 9 mo of gemcitabine. At the same time, the patient reported peripheral vascular disease without necrosis. Chemotherapy was suspended, and after one month the Positron Emission Tomography (PET) scan showed locoregional tumor recurrence. Gemcitabine was resumed and partial response was obtained, but peripheral vascular disease occurred.
CONCLUSION
Our results suggest that the appearance of peripheral vascular disease may be related to a prolonged response to gemcitabine.
背景
吉西他滨是一种用于治疗胰腺癌的抗代谢药物。吉西他滨的副作用之一是血管毒性。在此，我们报告一例接受吉西他滨治疗的患者，该患者患有外周血管疾病并伴有延长的抗肿瘤反应。
病例摘要
一名75岁男性被诊断为局部复发性胰腺癌。接受吉西他滨治疗9个月后取得部分缓解。与此同时，患者报告患有外周血管疾病但无坏死。化疗暂停，1个月后正电子发射断层扫描（PET）显示局部肿瘤复发。恢复使用吉西他滨后再次获得部分缓解，但外周血管疾病再次出现。
结论
我们的结果表明，外周血管疾病的出现可能与对吉西他滨的延长反应有关。
Zotero 插件